• Therapeutics, Inc.

The Company is recruiting industry leaders to positions including CEO (Dr. Daewoong Jo), CFO (Mr. Yeonseo Chung), CSO (Dr. Youngsil Choi), COO (Mr. Jungwook Kie), VP- Business Development, VP Clinical Development and Science & Business advisor (Dr. Earl Ruley). The core management will have a considerable amount of expertise in business, science, and drug development. 

The management team will evolve during the course of the startup and development stages. Our goal is to build the Company to a point in which it will be possible to recruit an outstanding senior management team and Board of Directors.


Dr. Daewoong Jo (CEO)

Dr. Daewoong JoFounding scientist, Dr. Daewoong Jo, is currently serving as CEO, President of the Company. Dr. Jo has continuously worked in the field of TSDT and protein-based drug development for past 18 years as a leading scientist, and recently, completed the TSDT platform development.

Dr. Jo received his Bachelors and Masters degrees in Biochemistry and Molecular Biology at Hanyang University, and subsequently, held positions as Scientist and Senior Scientist at the Yuhan Corporation-Research Center.

In 1997, Dr. Jo began his doctoral studies at Vanderbilt University, Nashville, Tennessee, USA and completed his dissertation research in Dr. Earl Ruley’s Laboratory. His thesis work involved the development of a cell-permeable Cre recombinase by utilizing hydrophobic cell-penetrating peptide (CPP). He showed it could be used to regulate gene structure and function in living cells and animals. His initial work was published in the prestigious journal, Nature Biotechnology. As measures of impact, this work led to a US patent and reagent requests from hundreds of laboratories around world-wide.? Dr. Jo went on to do a post-doc with Jacek Hawiger at Vanderbilt University after coming back from Sanger Institute, Hinxton, England. His work developing cell-permeable SOCS3 was truly a first-class innovation, and its publication in Nature Medicine was well-deserved.
Before establishing the Cellivery and taking the current position as CEO and president, he was an Assistant Professor of Biomedical Sciences at Chonnam National University Medical School, Kwangju, Korea from 2006 to 2010. During his sabbatical period, he was a visiting Professor of Department of Surgery at Vanderbilt University School of Medicine, Nashville, Tennessee, USA (2011-2014). In addition, Dr. Jo was a founder and CEO of another biotech company: ProCell Therapeutics, Inc., Seoul, Korea (2005-2010). 

At present, Dr. Jo is responsible for the planning and implementation of the development strategies in the Company’s business plan.

Science & Business Advisor : Dr. Earl Ruley

Science & Business AdvisorDr. Earl Ruley

Dr. Ruley is currently Professor of Pathology, Microbiology and Immunology at the Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 

He received Bachelor’s degree from the Stanford University, Ph.D. degree from the University of North Carolina, Chapel Hill, in 1980, and post-doctoral from the Imperial Cancer Research Fund in London, England. He has held Staff Scientist position at the Cold Spring Harbor Laboratory, and Assistant and Associate Professor at the Massachusetts Institute of Technology.? 

His research program has made significant contributions concerning basic mechanism of cell transformation by viral and cellular oncogenes, interactions between oncogenes and tumor suppressors, mammalian functional genomics, and the field of TSDT. Dr. Ruley has served on a number of advisory panels for both government and industry. He is co-founder of two biotech companies and holds two U.S patents. Dr. Ruley has published more than one hundred of research articles in peer-reviewed journals and was a mentor of Dr. Daewoong Jo’s doctoral study at Vanderbilt.

Mr. Jungwook Kie (CFO)

Mr. Jung-wook Kie He serves as head director of administration & planning headquarter and as COO at Cellivery. Mr. Kie earned BA from Yonsei University in Management and MBA from University of Michigan (Ann Arbor, Michigan, USA). Prior to joining Cellivery, he spent over 15 years at Hyundai Group, where he successfully served as a director of strategic planning division, financial strategy team. In this role, Mr. Kie was responsible for investment reports, fund raising, and equity management. Now, he dedicated himself in Cellivery’s future strategies development and supports all aspects of business development.



Dr. Youngsil Choi (CSO)

Dr. Youngsil Choi Dr. Choi joined Cellivery in 2014 and currently serves as chief scientist of New Drug Develoment & Business Develoment and CSO. She received her Bachelor degree in Biology at Kyunghee University, and obtained her Master and Ph.D. degrees in Cell Biology at Ewha Womans University, Seoul, Korea. In the two following years, she conducted her postdoctoral fellowship at the Research Center for Homeostasis of Ewha Womans University. Her research interests are focused on discovering new drugs to treat various cancers.



Dr. Youngryun Cha (Director of Neurodegenerative Disease Team)

Dr. Youngryun Cha Dr. Cha joined Cellivery in 2016 and currently serves as senior scientist of Neurodegenerative Disease Team. He received his Bachelor’s and Master degree in Biology at Inha University, and obtained his Ph.D. degrees in Cell Biology at Vanderbilt University, TN, USA. In the five following years, he conducted her postdoctoral fellowship at the NIH. His research interests are focused on research of Lymphangiogenesis.



Dr. Kuysook Lee (Director of Genome Engineering and Cell Fate Regulating Team)

Mr. Kyusook Lee Dr. Lee has joined Cellivery in 2015 and currently serves as Director of Genome Engineering and Cell Fate Regulating Team. She received her Bachelor’s and Ph.D. degrees in Cell Biology at Chonnam National University and has experience in research of cardiovascular disease at the KNIH.